Skip to content

Earnings call

Lupin Q2 FY26 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects its biosimilars portfolio to start positively contributing to U.S. revenues from fiscal year ‘27 and targets at least five products in the market by fiscal year ‘30. The company reported total revenue from operations exceeding INR 7,000 cr and EBITDA exceeding INR 2,100 crores for the first time in its history in Q2 fiscal year '26. The company had 180-day exclusivity for Tolvaptan extending into next week. Operating working capital stood at INR 7,730 crores as of 30th September, against INR 6,821 crores as of 31st March '25, equal to 102 days of working capital against 106 days in the previous quarter.

The numbers management gave

Results

  • The company reported total revenue from operations exceeding INR 7,000 cr and EBITDA exceeding INR 2,100 crores for the first time in its history in Q2 fiscal year '26.
    Show source
    We are truly delighted to announce a record quarter with total revenue from operations and EBITDA exceeding INR 7,000 cr and INR 2,100 crores, respectively, for the first time in our history.
  • India revenues grew 3.4% year-over year in Q2 fiscal year '26, while its core domestic formulations business grew 8.8%, or 1.2 times IPM growth; lower local tender sales within Global Institutional moderated the overall India number.
    Show source
    Switching to India, revenues grew 3.4% year-over year, with the core domestic formulations business delivering a healthy 8.8% growth, translating to 1.2 times IPM growth.
  • Domestic growth, excluding the impact of loss of exclusivity on products like Gibtulio® and Ajaduo®, stood at 10.7% YoY for H1.
    Show source
    Excluding the impact of loss of exclusivity on products like Gibtulio® and Ajaduo®, domestic growth stood at a robust 10.7% YoY for H1.
  • Other Developed markets, including Europe, Canada, and Australia, grew 19% YoY in Q2 fiscal year '26; Europe grew 26.8% YoY for Q2FY26 and 27.3% H1.
    Show source
    Our Other Developed markets, including Europe, Canada, and Australia, delivered 19% YoY growth, with Europe as the standout performer, growing 26.8% YoY for Q2FY26 and 27.3% H1.
  • Emerging markets grew 45% YoY in Q2 fiscal year '26, led by performance in Brazil and South Africa.
    Show source
    Our Emerging markets grew an impressive 45% YoY, led by strong performance in Brazil and South Africa.
  • Brazil business grew 141% in local currency, driven by successful diabetes product launches.
    Show source
    We are especially pleased with the turnaround in Brazil, which grew 141% in local currency, driven by successful diabetes product launches.
Show 12 more statements

Results

  • Employee benefit expenses were INR 1,106 crores in Q2 fiscal year '26, up 9.7% YoY from INR 1,007 crores in Q2FY25 and equal to 16.2% of sales versus 18.3% in Q2 last year; the increase largely reflected regular annual increments and business growth. Lupin Limited’s consolidated personnel cost was INR 11,056 Mn, or 16.2% of sales, in Q2 FY2026, compared to INR 10,075 Mn in Q2 FY2025.
    Show source
    Employee Benefit Expenses Employee benefit expenses at INR 1,106 crores increased 9.7% YoY from INR 1,007 crores in Q2FY25, translating to 16.2% of sales as compared to 18.3% in Q2 last year.
  • Manufacturing and other expenses were INR 1,980 crores in Q2FY26, up 18.8% YoY from INR 1,667 crores in Q2FY25 and from INR 1,772 crores in Q1 FY26, equal to 29% of sales versus 30.3% last year; the increase was mainly due to higher business volumes and certain one-time acquisition-related charges. Lupin Limited’s consolidated manufacturing and other expenses were INR 19,796 Mn, or 29.0% of sales, in Q2 FY2026, compared to INR 16,670 Mn in Q2 FY2025.
    Show source
    Manufacturing & Other Expenses Q2FY26 manufacturing and other expenses came in at INR 1,980 crores, increasing 18.8% YoY from INR 1,667 crores in Q2FY25 and INR 1,772 crores in Q1 FY26, translating to 29% of sales versus 30.3% last year.
  • R&D was INR 509 crores, or 7.5% of sales, in Q2 fiscal year '26, compared with INR 448 crores in Q2 last year; almost 70% of R&D was directed to its complex portfolio, reflecting its focus on complex and specialty platforms.
    Show source
    R&D R&D at INR 509 crores is 7.5% of sales as compared to INR 448 crores in Q2 last year, with almost 70% of our R&D directed to its complex portfolio.
  • EBITDA including Forex and other income was INR 2,138 crores in Q2 fiscal year '26 versus INR 1,308 crores in the same period last year, an increase of 63% YoY, with a margin of 31.3% versus 23.8%.
    Show source
    EBITDA EBITDA including Forex and other income was INR 2,138 crores vis -a-vis INR 1,308 crores in the same period last year, an increase of 63% YoY, with a margin of 31.3% vis -a-vis 23.8% last year in the same period.
  • Margins expanded by 470 basis points QoQ due to higher Gross margins and a lower fixed cost; margins reached 31.3% in Q2 fiscal year '26, expanding by 750 basis points YoY, the highest level recorded in the past many years.
    Show source
    Our margins have expanded by 750 basis points YoY and 470 basis points quarter-over-quarter reaching 31.3% the highest level recorded in the past many years.
  • Big therapy areas grew strong double-digit in Q2 fiscal year '26.
    Show source
    Again, our big therapy areas are growing strong-double-digit.
  • Volume growth was 5.2%, and its chronic segment represented 65% of its portfolio, up from 64% last fiscal; Lupin Limited saw strong volume growth in Q2 fiscal year '26.
    Show source
    Volume growth remained strong at 5.2%, while the chronic segment now represents 65% of our portfolio, up from 64% last fiscal.
  • The company said Tolvaptan and loss of exclusivity on a couple of products in India affected gross margins in the current quarter; once products turn generic, the margin percentage increases.
    Show source
    Ramesh Swaminathan: So, this particular quarter, there was essentially, the Tolvaptan factor, and also because of the fact that loss of exclusivity on a couple of products in India.
  • Margins reached 31.3% in Q2 fiscal year '26, expanding by 750 basis points YoY and 470 basis points quarter-over-quarter, the highest level recorded in the past many years. Replaced by a later filing.
  • Volume growth was 5.2%, and its chronic segment represented 65% of its portfolio, up from 64% last fiscal. Replaced by a later filing.
  • R&D spend was 7.5% of sales in Q2 fiscal year '26, reflecting its focus on complex and specialty platforms. Replaced by a later filing.

Money and capital

  • Operating working capital stood at INR 7,730 crores as of 30th September, against INR 6,821 crores as of 31st March '25, equal to 102 days of working capital against 106 days in the previous quarter.
    Show source
    Page 6 of 18 November 7, 2025 Operating Working capital Operating working capital stands at INR 7,730 crores as of 30th September, against INR 6,821 crores as of 31st March '25, which translates to 102 days of working capital against 106 days in the previous quarter.

What it expects ahead

What management expects

  • The company expects its biosimilars portfolio to start positively contributing to U.S. revenues from fiscal year ‘27 and targets at least five products in the market by fiscal year ‘30.
    Show source
    In addition, we expect our biosimilars portfolio to start positively contributing to U.S. revenues from fiscal year ‘27, and we target to have at least five products in the market by fiscal year ‘30.
  • The company has over 80 new product launches planned over the coming years, including innovative products from in-house development and in-licensing.
    Show source
    We have over 80 new product launches planned over the coming years, including innovative products from both in -house development and in-licensing.
  • The company expects to be in the first wave of GLP -1 launches with Semaglutide in India.
    Show source
    This includes GLP -1s, where we expect to be in t he first wave of launches with S emaglutide in India and are working on strengthening our innovation pipeline for the long term.
  • Other Developed markets represented 12% of total sales, up from 11% two years ago, and are expected to expand further as the company rolls out new products.
    Show source
    These markets now represent 12% of total sales, up from 11% two years ago, and are expected to expand further as we roll out our robust pipeline of new products.
  • Global specialty business will reach USD 150 million annualized revenues next year following the VISUfarma acquisition.
    Show source
    It will bring ou r global specialty business to USD 150 million annualized revenues next year, starting to build some scale.
  • The company has over 50 product filings planned for the U.S., with a near-term focus on respiratory, complex injectables and biosimilars.
    Show source
    We have over 50 product filings planned for the U.S., with a near-term focus on respiratory , complex injectables and biosimilars.
Show 19 more statements

What management expects

  • The company expects an increasing share of R&D investments to flow into specialty programs and value-added medicines, including long-acting injectables, green propellant-based products, and 505(b)(2)s.
    Show source
    Page 3 of 18 November 7, 2025 Over time, we expect an increasing share of R&D investments to flow into specialty programs and value-added medicines, including long-acting injectables, green propellant-based products, and 505(b)(2)s. We also plan to strengthen our innovation ecosystem in India through both in-house development and in licensing of late-stage assets.
  • The company expects full-year R&D to be around 7.5% to 8.5%.
    Show source
    For the full-year, as indicated, we expect R&D to be around 7.5% to 8.5%.
  • The company expects full-year EBITDA margins to be 25% to 26%, higher than its earlier guidance of 24% to 25%.
    Show source
    We expect full-year EBITDA margins to be in the range of 25% to 26%, higher than our earlier guidance of 24% to 25%.
  • ETR is expected to be about 20.9% for H1.
    Show source
    ETR Turning to the tax rate, ETR is expected to be about 20.9% for H1 .
  • The company expects full-year ETR to be around 21% to 22%.
    Show source
    For the full-year, we expect ETR to be around 21% to 22%.
  • The company expects some erosion from USD 315 million in the second half, but expects to be close to between USD 275 million to USD 300 million per quarter and close over USD 1 billion as previously guided.
    Show source
    So, as we look at the next couple of quarters, the second half, we certainly think that we'll have some erosion f rom this USD 315 million, but Page 7 of 18 November 7, 2025 we should be, close to between USD 275 million to USD 300 million per quarter to close over USD 1 billion as we have guided in the past.
  • The company expects EBITDA margins of around 24% - 25% next year, with some products sustaining momentum.
    Show source
    And given the fact that we expect some of the products to kind of sustain the momentum, we would think that we would be able to close at around 24% - 25% next year as well.
  • The company would love to grow 20% plus every year in Europe and expects growth higher than the company average growth rate in European countries on at least a three to five year basis, facilitated by the VISU acquisition.
    Show source
    Vinita Gupta: So, Europe in particular, we have a pretty strong portfolio pipeline of products to drive growth, and we would love to grow 20% plus every year, but I'd say at least on a three to five year basis we should see higher than the company average growth rate in countries in Europe, facilitated now with the VISU acquisition as well.
  • The company expects EBITDA margins around the 24%-25% mark, accounting for a possible slight reduction in gross margins that could be made up through operating leverage and other parts.
    Show source
    So, there could be a decline, but having said that the EBITDA margins being around the 24%-25% mark., This obviously takes into account the fact that there could be a slight reduction in the gross margins line, but made up in some ways through operating leverage and other parts .
  • The company is on track to double the share of complex products in its U.S. business over the next few years.
    Show source
    Altogether, this sets us on track to double the share of complex products in our U.S. business over the next few years.
  • The company expects overall margins in H2 to be tempered by higher R&D spends and a lower PLI income.
    Show source
    Whilst we expect business to continue to exhibit robust performance, overall margins in H2 would be tempered by higher R&D spends and a lower PLI income.
  • The company expects some competition for Tolvaptan, but believes that not both of the two expected competitors may enter.
    Show source
    We would expect some competition, but we also believe that the two competitors that we're expecting, not both of them may make it.
  • The company said the TAs are delayed and it does not see any TAs as of yet, so it expects more of a runway for Tolvaptan.
    Show source
    The TAs are delayed, we don't see any TAs as of yet, so we do think that we are going to get more of a runway .
  • The company is about to launch the Risperdal Consta® product in the next couple of weeks.
    Show source
    We are about to launch the Risperdal Consta® product in the next couple of weeks.
  • The company expects sales growth next year, with opportunities in other parts of the globe, including India with Semaglutide.
    Show source
    So, from a sales perspective, we think there would be growth.
  • The company expects the comparison perspective next year to be a little lacklustre versus the current year.
    Show source
    I'll bet it's going to be a little lacklustre from a comparison perspective vis-a-vis the current year.
  • Brazil diabetes franchise growth is driven by launches of Dapagliflozin and Empagliflozin; the company got approval for Empagliflozin this week and is hopeful it can drive growth in Brazil.
    Show source
    Page 10 of 18 November 7, 2025 In Latin America, Brazil in particular, it really has been a turnaround aided by a really good product launch in the diabetes franchise, Dapagliflozin, as well as this week, we got approval for Empagliflozin, so we are hopeful to be able to drive growth in Brazil on the diabetes franchise overall.
  • The company restructured its South Africa portfolio and doubled down on products where it sees potential for future growth, and hopes to sustain the current year's growth rate in the next few years.
    Show source
    We have doubled down on products where we see potential of growth going forward and are hoping to sustain the growth rate that we have in the current year in the next few years ahead.
  • South Africa is the other key market for Lupin Limited's Semaglutide opportunity, alongside India; the Philippines may be a market at some point.
    Show source
    I think these will be the two key markets, maybe at some point of time in Philippines, but that's it.

What it is building and selling

Projects and capacity

  • The company is progressing clinical trials for the DM1 and DM2 indications for global commercialization, particularly in the U.S. and Europe.
    Show source
    So, we're continuing to progress the clinical trial on the DM1 and DM2 indication for global, in particular U.S., and Europe, commercialization.
  • The company has Semaglutide and Tirzepatide in the works as other peptides.
    Show source
    And in terms of other peptides, we have Semaglutide in the works, we have Tirzepatide in the works, so we have other peptides in the works as well.
  • The company is building in-house capability for peptides, while also doing peptide work partially in-house.
    Show source
    Vinita Gupta: So, partially in-house and we're also building our own capability on the peptide front.
  • The company is making the cartridge for its Respimat line in India and packaging it in Coral Springs; for Ellipta, it selected a pretty automated line because the cost difference was marginal and locating manufacturing near the R&D site benefits scale-up and manufacturing.
    Show source
    We're doing the cartridge in India and we're doing the packaging in Coral Springs.
  • The company decided to make the investment in the U.S. after comparing setting up in India and Coral Springs.
    Show source
    So, overall, we felt pretty good about making the investment in the U. S. Tushar Manudhane: And the devices with respect to these products.

Demand and pricing

  • The company had 180-day exclusivity for Tolvaptan extending into next week.
    Show source
    Vinita Gupta: On Tolvaptan, we have 180-day exclusivity, so that's into next week.
Show 11 more statements

Demand and pricing

  • The company said 30% of the Tolvaptan market had converted, leaving room for generic penetration and expansion of the market for Lupin and new entrants.
    Show source
    Plus, if we look at Tolvaptan conversion so far, we have seen 30% of the market convert, so there's still a lot of room for generic penetration and an expansion of the market overall for both for us as well as new entrants.
  • The market grew 8% in H1; Lupin Limited grew 8.8% in Q2FY26, or more than 10% excluding the LOE part.
    Show source
    Nilesh Gupta: I mean, for H1, the market grew 8%, so I would say that the market is pretty decent from a growth perspective, from our perspective we grew at 8.8% in Q2FY26, 10% plus if I take out the LOE part.
  • The company sees near term tailwinds for its respiratory and diabetes portfolio from the revival of the Respiratory category and the exit of Mixtard in the insulin market.
    Show source
    With the revival of the Respiratory category and the exit of Mixtard in the insulin market, we see near term tailwinds for both our respiratory and diabetes portfolio.
  • Albuterol business has stabilized, but Amneal will likely enter at some point, causing further erosion.
    Show source
    Vinita Gupta: So, Albuterol has stabilized, but we see Amneal will likely come in at some point in time.
  • Spiriva® share has stabilized, but the company has not been able to get good access on the Medicare front; it is hopeful of gaining additional share in the quarters ahead amid the U.S. administration's focus on biosimilars and generics for CMS business.
    Show source
    On Spiriva®, our share has stabilized.
  • The company has not heard of any material progress of competition for Spiriva®.
    Show source
    We haven't heard of any material progress of a competition.
  • The company has started to see some gain in share on the Medicare front, but it remains small compared with the opportunity.
    Show source
    I mean, so we have started to see some gain and share on the Medicare front, but it's still small compared to the opportunity.
  • The Mirabegron market has grown, and the innovator has held on to a good percentage of share; Vinita Gupta said the earlier guidance might have been very conservative.
    Show source
    Vinita Gupta: So, the market has grown for Mirabegron and innovator has also held on to a good percentage of share and I think if I'm not mistaken, the earlier guidance might have been very conservative.

Segments

  • The company recently launched the authorized generic to Ravicti®, which it described as a material launch.
    Show source
    And then in terms of new launches, just recently we launched the authorized generic to Ravicti®, which is a material launch for us.
  • The company assembles the devices for its products from components it receives.
    Show source
    Vinita Gupta: No, we're actually assembling the devices.

Deals and partners

  • The company has in-licensed Semaglutide for both India and South Africa.
    Show source
    Vinita Gupta: And from a capacity standpoint, they are in -licensed both for India as well as South Africa.

Risks, rules and outside factors

Risks and disputes

  • The company received VAI status for its Pithampur Unit 3 respiratory facility and is actively addressing the OAI at Unit 2.
    Show source
    On the compliance front, we recently received VAI status for our Pithampur Unit 3 respiratory facility and are actively addressing the OAI at Unit 2.

Everything else said on the call

What management stressed

  • The company is focused on respiratory, neurology/CNS and ophthalmology; it plans to continue building its NaMuscla® neurology/CNS business and ophthalmology business, including in the U.S., Europe and other parts of the world.
    Show source
    Vinita Gupta: So, we are focused on three therapy areas.
  • The company is working on alternate vendor development initiatives to improve its gross margin line. Replaced by a later filing.
    Show source
    Clearly, we're working on a number of initiatives in terms of a lternate vendor development and stuff like that, in terms of wanting to move the gross margin line.

Group structure

  • Planned acquisition of VISUfarma includes a portfolio of 60 plus innovative eye health products and established infrastructure, and aligns with its strategy to expand its European footprint and build a global specialty franchise.
    Show source
    The planned acquisition of VISUfarma, with its portfolio of 60 plus innovative eye health products and established infrastructure, aligns well with our strategy to expand a European footprint and build a global specialty franchise.
  • Acquisition of VISUfarma is expected to close by 2025 and enhance growth and margins, adding diversity across key European markets.
    Show source
    This acquisition, expected to close by 2025, will enhance both growth and margins, adding diversity across key European markets.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Kunal Dhamesha: The first question on the U.S. business, now that we probably have seen a good amount of Tolvaptan in this quarter, how do we see this USD 315 million number moving in the coming quarters? And also, what are the key launches that we are looking at, both in second half of FY26 and first half of FY27?

    Answer, vinita gupta

    Vinita Gupta: On Tolvaptan, we have 180-day exclusivity, so that's into next week. We would expect some competition, but we also believe that the two competitors that we're expecting, not both of them may make it. The TAs are delayed, we don't see any TAs as of yet, so we do think that we are going to get more of a runway . Plus, if we look at Tolvaptan conversion so far, we have seen 30% of the market convert, so there's still a lot of room for generic penetration and an expansion of the market overall for both for us as well as new entrants. So, as we look at the next couple of quarters, the second half, we certainly think that we'll have some erosion f rom this USD 315 million, but Page 7 of 18 November 7, 2025 we should be, close to between USD 275 million to USD 300 million per quarter to close over USD 1 billion as we have guided in the past. And then in terms of new launches, just recently we launched the authorized generic to Ravicti®, which is a material launch for us. We are about to launch the Risperdal Consta® product in the next couple of weeks.

    Answer, vinita gupta

    We have an upcoming goal date for Pegfilgrastim, for which we had a recent inspection at the biotech facility. Feel pretty good about that, so that should be coming up. Victoza® was just launched, so we'll see the ramp up of that. So, injectables certainly, Ravicti® plus biosimilars into the next couple of quarters, and then Ranibizumab next year, we feel pretty good about sustaining a USD 1 billion plus level into fiscal year '27.

  2. Question

    Kunal Dhamesha: Second question on the EBITDA margin guidance for FY26, which we have raised by almost 100 basis points. But how to look at FY27, how should we kind of look forward to the EBITDA margin for the year?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: We expect a reduction in the second half. But we have also said in the same breath that there would be an increase in the R&D expenditure. But we do expect the R&D expenditure next year to kind of normalize a little vis -a-vis, in fact, the second half. And given the fact that we expect some of the products to kind of sustain the momentum, we would think that we would be able to close at around 24% - 25% next year as well. And there's, of course, opportunities in other parts of the globe, like as in India with Semaglutide and the like. So, from a sales perspective, we think there would be growth. I'll bet it's going to be a little lacklustre from a comparison perspective vis-a-vis the current year.

    Answer, ramesh swaminathan

    But overall, there would be we would be able to kind of keep to the margins that we are speaking about.

  3. Question

    Kunal Dhamesha: In terms of the recent inspection at the Nagpur facility, have we submitted a response? And how important is this facility for us from a future growth perspective, specifically from FY27 and FY28 perspective?

    Answer, nilesh gupta

    Nilesh Gupta: The audit was for our injectable facility. So, we've obviously submitted the response. And I think the next update where we've made a lot more progress actually goes in today. We're not happy with the observations, but we believe that they are addressable. We're obviously putting our best foot forward at this point of time with the response. And we hope that it will suffice. It is important, both for our injectables, which are just starting to build at this point of time and some of our biotech products as well.

    Answer, nilesh gupta

    The facility is important and obviously we want to keep it in a state of good compliance. Obviously, we're going to do whatever it takes to get it to the finish line.

  4. Question

    Kunal Dhamesha: Can you share the number of ANDAs from the facility which are pending?

    Answer, nilesh gupta

    Nilesh Gupta: We've just started our injectable journey. So I think we've just got a few approvals and we file 5-6 ANDAs every year. So, I mean, we're not talking about a very large number yet, but I mean, it's a key part of what we want to build going forward.

    Answer, vinita gupta

    Vinita Gupta: We don't give product-wise guidance, but needless to say that Tolvaptan has been a significant contributor in Q2. Bino Pathiparampi l: And how is Mirabegron? Does it fluctuate quarterly or are you maintaining a roughly same run rate ?

    Answer, vinita gupta

    Vinita Gupta: No, Mirabegron has also grown QoQ. Bino Pathiparampil: How do you think about that product? In February there is this hearing. Do you expect a decision around Feb or March itself or is it likely to go on for some time?

    Answer, vinita gupta

    Vinita Gupta: It is hard to predict how the judge will rule, or the jury will rule. But based on the trial that we have seen so far, I mean, in the case of MSN that settled, and Ascent last week. We feel pretty good about not really seeing any new entrants in the near term. And then, as our trial date comes closer, we'll see how the rest of the competitive base is going to really factor the risk for the launches. But we also feel good about the fact that our case where we have a number of defences on the non-infringement front, we feel pretty good about it as the trial comes closer.

  5. Question

    Bino Pathiparampil: My question was specifically, once the trial starts in Feb, do you expect a final decision in your favour or against within a month or so? Or is the trial likely to go on for months?

    Answer, vinita gupta

    Vinita Gupta: Usually, jury trials don't go on for months, but the decision from the jury is hard to predict if they’re going to make the decision right away.

  6. Question

    Bino Pathiparampil: Last question on EMEA growth, very strong numbers growth, partly helped by currency depreciation, I assume, but even adjusted for that it's very strong. Anything in particular that is driving that?

    Answer, vinita gupta

    Vinita Gupta: So Luforbec® continues to be a very strong performer. We continue to grow our share in Luforbec® in the current countries where we already present as well as in new countries that we have launched. Raltegravir was also a good contributor to revenues in the quarter. So, both respiratory as well as other products.

  7. Question

    Shyam Srinivasan: Just one on the VISUfarma acquisition. If you could walk us through the strategic rationale. I think the presentation also talked about being accretive to margins. I can see some of the margins, but just the thought process on that acquisition and what does it essentially add to our portfolio?

    Answer, vinita gupta

    Vinita Gupta: We have always said that we are under-indexed in Europe and we have significant potential headroom there but didn't have the right market presence. We had presence in UK, Germany and France very recently. This adds Italy and Spain to us. So that's number one. Page 9 of 18 November 7, 2025 And with the infrastructure that we gained, we also have the ability to launch the Lupin portfolio into those countries, even though, the business that we're acquiring is ophthalmics . But with the infrastructure you get, especially the common resources, our team is also confident of launching other products into these markets direct as opposed to partner business that we do in Italy and Spain like countries. Second, ophthalmology as a specialty franchise is one that we've been excited about the last couple of years.

    Answer, vinita gupta

    We have been looking at multiple assets, both in U.S. and Europe. And this VISUfarma, we had gotten to know the company over the last couple of ye ars and tracked them very closely. And really liked the momentum that they had built both on the commercial front, as well as the pipeline front. So, it really sets us up very nicely for to build ophthalmology franchise, both in Europe, as well as potentia lly the U.S. and Other Developed Markets going forward. Third, I would say that we have synergies on the pipeline portfolio from VISU into other markets, and particularly, the Emerging markets, Mexico, where we have ophthalmic business, other countries in Latin America, Southeast Asia. And we're looking at the potential also in countries like Canada and Australia, we intend to bring the VISU portfolio into as many markets as we can. So, a combination of expanding our footprint in Europe, as well as building on the specialty franchise with ophthalmology and operating leverage through global maximization of portfolio.

    Answer, vinita gupta

    Vinita Gupta: So, we have Xopenex® in the U.S. that is the one brand in the U.S. right now. We hope to be able to build on that. We have Zaxine ® in Canada, for IBS, and we have NaMuscla® in Europe. Shyam Srinivasan: And the time frame for this EUR 150 million would be fiscal ’27, is it, or later?

  8. Question

    Saion Mukherjee: We have seen very strong growth in some of the emerging markets like Brazil, South Africa, you mentioned, and also in Europe. How should we think about the growth, because the numbers are very high, so is this number sustainable? And on this pace, how should we think about growth, if you can take us through in these markets, and what will drive that ?

    Answer, vinita gupta

    Vinita Gupta: So, Europe in particular, we have a pretty strong portfolio pipeline of products to drive growth, and we would love to grow 20% plus every year, but I'd say at least on a three to five year basis we should see higher than the company average growth rate in countries in Europe, facilitated now with the VISU acquisition as well. Page 10 of 18 November 7, 2025 In Latin America, Brazil in particular, it really has been a turnaround aided by a really good product launch in the diabetes franchise, Dapagliflozin, as well as this week, we got approval for Empagliflozin, so we are hopeful to be able to drive growth in Brazil on the diabetes franchise overall. South Africa, we really turned around the business again. It was flat over a couple of years. We have restructured the portfolio. We have doubled down on products where we see potential of growth going forward and are hoping to sustain the growth rate that we have in the current year in the next few years ahead.

  9. Question

    Saion Mukherjee: Second question would be on biosimilars and respiratory. If you can take us through the key milestone that we need to watch out for, you mentioned five products commercialization in biosimilar till fiscal '30. If you can take us through the product and time line and also on the key respiratory filings where we are and what's the time frame for commercialization ?

    Answer, vinita gupta

    Vinita Gupta: On the biosimilars front, Pegfilgrastim is in the next couple of weeks. We have a goal date in end of this month. So that will be our first one. We have Ranibizumab middle of next year, the goal date. And I feel pretty good about that one because I think they're the first prefilled syringe filed in the U.S . Also, currently, the two biosimilars that were on the market are out of the market. Presumably because of pricing concerns and probably will come in at a different price point.

    Answer, vinita gupta

    So, that presents a really nice opportunity. Then we have the on-body product, Pegfilgrastim that we've made progress on. And we'll expect that to be third to market. And fourth will be Eylea® building on the ophthalmic after the Ranibizumab launch. Fifth will be Etanercept, because of the submarine patent in the U.S. is out to FY29. But we'll expect to launch Etanercept as well in the five -year time frame. So those are the products on the biosimilars front.

    Answer, vinita gupta

    On the respiratory front, we are making progress on Dulera that we've already filed. And we are pretty far along now on Respimat, with the Spiriva Respimat® product. And hope to really, by the end of this fiscal year, provide more of an update there on the concrete dates from a filing perspective. And we're also making progress on the Ellipta franchise with Breo®, Trelegy® as well, and Anoro®, all three products are in development. And then we have made substantial progress on the green propellant front, especially for Europe, where with Luforbec®, the green Luforbec® is an important part of our five year plan in the European markets. Plus Trimbow®, we have actively under development. As well as other U.S. products, we have green propellant versions in development as well.

  10. Question

    Saion Mukherjee: Just one clarification, I mean all these products that you mentioned, should we expect filings in FY 27, that is next fiscal year ?

    Answer, vinita gupta

    Vinita Gupta: Maybe not all of them, but it's a good percentage of them .

Show 16 more questions
  1. Question

    Neha Manpuria: On gross margins, how should I look at it, given we had a lot of moving parts and benefit in this quarter. From a full -year perspective, based on what happens to Tolvaptan, what should be a reasonable assumption for gross margin levels?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: So, this particular quarter, there was essentially, the Tolvaptan factor, and also because of the fact that loss of exclusivity on a couple of products in India. So, once it turns generic, clearly margins also increase because the margin percentage that has increased. So, that's the story so far as this current quarter is concerned. Clearly, we're working on a number of initiatives in terms of a lternate vendor development and stuff like that, in terms of wanting to move the gross margin line. So, there could be a decline, but having said that the EBITDA margins being around the 24%-25% mark., This obviously takes into account the fact that there could be a slight reduction in the gross margins line, but made up in some ways through operating leverage and other parts . Neha Manpuria : On biosimilars, something like , Pegfilgrastim, which is already a competitive market, Ranibizumab, we've seen players exit because of pricing. What do you think of, how does Lupin see itself positioning competitively to gain market share there ?

    Answer, vinita gupta

    Vinita Gupta: So, on Pegfilgrastim, actually, there's been a lot of interest from partners that are in the oncology space already. And just given the dynamics of the biosimilars market where a new product coming in, even after multiple competitors can set a reasonable A SP, we see tremendous opportunity, in terms of share. Certainly, it's going to be a smaller percentage compared to other products where we'll have limited number of players. But in terms of dollars, it should be a nice contributor into the ne xt couple of years, fiscal year '27 as well as fiscal year '28. So, Pegfilgrastim in particular, we plan to partner, so we're not going to build any commercial infrastructure. But on the ophthalmic front with Ranibizumab, where again we see an opportunity of launching at a reasonable price, I'd say, that gives room both for the providers as well as for us as a manufacturer. We expect to have some infrastructure to be able to sell through to the ophthalmic distributors and also ensure that we get the fulfilment .

    Answer, vinita gupta

    Vinita Gupta: Eylea® is fiscal year ‘ 28 or fiscal year ‘29. I think it's at the tail end of FY28, early FY29.

  2. Question

    Neha Manpuria: And from capital allocation, I think in the opening remarks, there was a mention of investing more in specialty. Given the investments we have in ophthalmology with VISUfarma and also separately in the NaMuscla®, in CNS, will this be the two areas that would focus on for incremental deals in specialty? Would that be the road you would go down to, or you're open to looking at other therapy areas as well ?

    Answer, vinita gupta

    Vinita Gupta: So, we are focused on three therapy areas. Respiratory continues to be a focus just given the scale we have on respiratory, both U.S., Europe, other developed markets, as well as India. Second, in the NaMuscla® neurology, CNS is an area that we'll continue to build. But so far, on that front, we are building on the DM indication. So, we're continuing to progress the clinical trial on the DM1 and DM2 indication for global, in particular U.S., and Europe, commercialization. And then ophthalmology is the third area that we have actually looked at in the past. But VISUfarma gives us a nice start and will continue to build on the ophthalmology in U.S., Europe, as well as other parts of the world.

  3. Question

    Shashank Krishnakumar: First one on Risperidone, which we plan to launch this quarter. I wanted to check if this is a shared CGT Exclusivity?

    Answer, vinita gupta

    Vinita Gupta: So, we believe that we should be the next one in and Amneal that has also got approval will launch later. But we will have a shared exclusivity with them when they can launch certainly when they get approved.

  4. Question

    Shashank Krishnakumar: And on Mirabegron, I think I missed your comments. On base cases, no incremental competition in the near-term. Is that the right understanding?

    Answer, vinita gupta

    Vinita Gupta: Yes. We have a base case where there is no additional competition in the near term.

  5. Question

    Surya Patra: And in the meanwhile, I think the growth of the industry itself has muted. So, do you think that is having some impact to the overall industry growth trend in the domestic market and hence your growth may not be double -digit? Anything of that sort?

    Answer, nilesh gupta

    Nilesh Gupta: I mean, for H1, the market grew 8%, so I would say that the market is pretty decent from a growth perspective, from our perspective we grew at 8.8% in Q2FY26, 10% plus if I take out the LOE part. Again, our big therapy areas are growing strong-double-digit. And importantly, we're seeing strong volume growth as well. So, I'm cautiously optimistic on the market .

  6. Question

    Surya Patra: Second question is about the respiratory business . One is that we have indicated about a long-term investment plan of around USD 250 million in the U.S. And simultaneously we have also kind of adopted the Honeywell Solstice® propellant for our inhalers. So, how is this changing the business opportunity or any competitiveness or the scope if you can discuss that part ?

    Answer, vinita gupta

    Vinita Gupta: One I'll address two different questions . First on the investment in the U.S. that we announced the USD 250 million a combination of both Capex as well as pipeline is for the Respimat as well as Ellipta franchise which we had planned to commercialize from our U.S. Coral Springs site. So that is the investment in terms of pipeline, all the products on the Ellipta® franchise, and all the products on the Respimat franchise plus we're going to have a MDI line as well that gives us the access to government business in the U.S., also helps us diversify risk a little bit on the MDI front with Albuterol as well as other MDIs in the future. So that was part of our plan already and has got very positive response from all the stakeholders in DC that we have talked to, so the fact that we are investing in the U.S. has been received positively. On the green propellant front, we see a number of opportunities both in Europe as well as the U.S., maybe the near term in Europe but also in the long term the U.S. You see the large majors like companies like GSK, AstraZeneca as well as Chisi in Europe all have been working on low GWP weight propellants, just given all the concerns of climate change. And we expect that, end of this year, Ventolin® to be filed with the new propellant in the U.S. There already have been multiple filings in Europe.

  7. Question

    Vishal Manchanda: And so, you believe you have enough capacities for a fair share?

    Answer, vinita gupta

    Vinita Gupta: Yes, for the current products. You know, as we're looking at biosimilars going forward, given the momentum now, the FDA doing away with the requirement of clinical studies, certainly for products where we can be in the first wave, where they're going to be limited competitors, we want to now target the next round of pipeline on the biosimilars front. So, we'll have to take a look at what we will need in terms of capacities going forward.

  8. Question

    Saion Mukherjee: And you won't be looking at the India markets?

    Answer, vinita gupta

    Vinita Gupta: We are absolutely looking at the India market as well.

  9. Question

    Damayanti Kerai: My question is regarding Liraglutide. Vinita, how do you see this opportunity given market has clearly moved towards new gen products? And then do you have more peptides which are in pipeline to be filed in U.S. in near term?

    Answer, vinita gupta

    Vinita Gupta: So, we've just recently launched it. We're going to really over the next couple of months be able to determine what kind of market will the generic switch and also our own share. But it's been a very recent launch for us. And in terms of other peptides, we have Semaglutide in the works, we have Tirzepatide in the works, so we have other peptides in the works as well.

  10. Question

    Damayanti Kerai: And these are done through CMO’s or you're doing in-house?

    Answer, vinita gupta

    Vinita Gupta: So, partially in-house and we're also building our own capability on the peptide front. And just given the limited capacities available for peptides in the market, expanding significantly, especially after Semaglutide goes generic and starting next year in India and few other markets. So, we're building in- house capability.

  11. Question

    Tushar Manudhane: Just on this Coral Springs investment, conceptually Indian facilities is at a lower cost of manufacturing and that has been one of the advantage for the exports business. So, from that perspective, if you want to think about then how does this investment plays out from the profitability point of view? Page 16 of 18 November 7, 2025 Vinita Gupta: So, we looked at setting it up in India as well as Coral Springs and overall, the lines for both Respimat as well as Respimat, we're doing a combination of the two.

    Answer, vinita gupta

    We're doing the cartridge in India and we're doing the packaging in Coral Springs. And for Ellipta, it's a pretty automated line , and we really felt the difference was marginal, but there was an advantage of having the manufacturing site close to the R&D site, both for effective scale up as well as manufacturing. So, overall, we felt pretty good about making the investment in the U. S. Tushar Manudhane: And the devices with respect to these products. So, again, this is procuring from the top three, four global players. Is that how the thought process is going to be?

    Answer, vinita gupta

    Vinita Gupta: No, we're actually assembling the devices. So, we get the components and we assemble it.

  12. Question

    Saion Mukherjee: On Semaglutide opportunity for next year, how are you thinking? You mentioned about India and then how many other markets, how many of them you think you would be in the first wave? And if you can talk about capacity and your overall expectation on the market dynamics?

    Answer, nilesh gupta

    Nilesh Gupta: South Africa is the other market that we have. I think these will be the two key markets, maybe at some point of time in Philippines, but that's it. But I think what will really make a difference is largely India and a little bit of South Africa. Vinita Gupta: And from a capacity standpoint, they are in -licensed both for India as well as South Africa. Saion Mukherjee: It's possible for you to share the kind of capacities you have in place for next year?

  13. Question

    Saion Mukherjee: And my next question would be on the respi products in the U.S. So, Albuterol has seen erosion. So, is it still declining or has that stabilized? And also, if you can comment on Spiriva ®, for you, has it stabilized now or it has come off from the peak? And if you have any expectation, updated expectation on possible competition, and when that happens how do you see revenues move in that product?

    Answer, vinita gupta

    Vinita Gupta: So, Albuterol has stabilized, but we see Amneal will likely come in at some point in time. So, there will be further erosion. On Spiriva®, our share has stabilized. At the same time, there is this new momentum of the government, U.S. administration , trying to focus on biosimilars and generics as a priority for CMS business, which is where we are struggling right now on Spiriva®. We Page 17 of 18 November 7, 2025 haven't been able to get good access on the Medicare front. We are hopeful that we will be able to drive additional share with this new momentum in the quarters ahead. We haven't heard of any material progress of a competition.

  14. Question

    Saion Mukherjee: And with a Medicare access, when do you see that playing out for you?

    Answer, vinita gupta

    Vinita Gupta: So, Medicare, they have actually prioritized the brand. Everything that they're saying right now that they want to prioritize biosimilars and a generic-first policy. It's hard to predict when, right? I mean, so we have started to see some gain and share on the Medicare front, but it's still small compared to the opportunity.

  15. Question

    Kunal Dhamesha: Can you give a split for our India business between the prescription business and the adjacency businesses?

    Answer, nilesh gupta

    Nilesh Gupta: It's almost entirely the prescription business. I think the adjacencies will be less than a couple of percent.

  16. Question

    Kunal Dhamesha: And then secondly, on Mirabegron, innovator seems to hav e raised their guidance for the U.S. market by almost 80%. So, is it because of very strong demand in terms of volumes? What kind of dynamics are playing out there ?

    Answer, vinita gupta

    Vinita Gupta: So, the market has grown for Mirabegron and innovator has also held on to a good percentage of share and I think if I'm not mistaken, the earlier guidance might have been very conservative.

    Answer, vinita gupta

    Vinita Gupta: Thank you, friends, for all your questions. We have had really strong performance in the last couple of quarters. Look forward to working on continuing this trajectory in the quarters and years ahead and will look forward to connecting with you next quarter. Thank you. And have a great weekend.

Questions about this call

When was the Lupin Q2 FY26 earnings call transcript filed?
Lupin filed the transcript with the exchange on 12 Nov 2025. This page is built from that transcript.
What does this page list?
65 statements from the transcript across 10 topics, 38 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 26 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Lupin Q2 FY26 concall: what the company said · DalalOS